GlassScriptPhysician profile
John M Wattenbarger
NPI 1043294598
$339,772.38
in general payments reported to CMS, 2019-2025
9 companies · $66K in 2025
The $66K reported for 2025 was more than what 96% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $33K · 2021: $44K · 2022: $47K · 2023: $55K · 2024: $55K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $175K · Food and Beverage: $62.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $175,106.46 |
| Food and Beverage | $62.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthopediatrics Corp. | $339,447.55 | 2019-2025 | |
| Medical Device Business Services, INC. | $84.43 | 2019 | |
| Saol Therapeutics INC. | $81.08 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $58.83 | 2019-2020 | |
| Depuy Synthes Sales INC. | $33.53 | 2021 | |
| Masimo Corporation | $22.80 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $17.60 | 2022 | |
| Nuvasive, INC. | $13.47 | 2019 | |
| Medtronic USA, INC. | $13.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wattenbarger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.